Cochrane Abstracts
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer. Accessed 25 September 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer. Accessed September 25, 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer
Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer [Internet]. In: Cochrane Abstracts. [cited 2023 September 25]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
ID - 431195
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer
DB - Evidence Central
DP - Unbound Medicine
ER -
